Cellectar Biosciences CLRB
NASDAQ CLRB
$1.26 +0.03 (+2.44%)
As of: Oct 21, 2026 · 10:10 AM EDT

Cellectar Biosciences (CLRB) Convertible Debt (2010 - 2014)

Updated

Cellectar Biosciences (CLRB) reported Convertible Debt of $3.8 million for Q2 2014, up 0.8% from the prior quarter.

Analysis

Cellectar Biosciences (CLRB) Convertible Debt (2010 - 2014) Analysis & Trends

At the end of FY2010, Cellectar Biosciences posted Convertible Debt of $2.72 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,132.34 Bn 1,100.93 Bn 19.71 Bn
2 Johnson & Johnson 615.91 Bn 534.44 Bn 17.26 Bn
3 AbbVie 505.47 Bn 478.59 Bn 12.70 Bn
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn
5 Novartis Ag 298.18 Bn 262.17 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 236.22 Bn 191.62 Bn 7.24 Bn
8 Gilead Sciences 190.68 Bn 164.87 Bn 6.22 Bn
9 Pfizer 170.14 Bn 116.79 Bn 10.94 Bn
10 Cellectar Biosciences 15.41 Mn -55.37 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2014 3.80 Mn
Mar 31, 2014 3.77 Mn
Dec 31, 2010 2.72 Mn
API Access

Cellectar Biosciences Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=CLRB&period=max&api_key=YOUR_API_KEY